| Notice of References Cited | Application/Control No. 10/748,342 | Applicant(s)/Patent Under Reexamination DOMBROSKI ET AL. | |
|---|---|---|---|
| | Examiner Anthony J. Paviglianiti | Art Unit 1626 | Page 1 of 2 |

**U.S. PATENT DOCUMENTS**

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Name | Classification |
|---|---|---|---|---|---|
| * | A | US-6,534,492 | 03-2003 | Carlsen et al. | 514/183 |
| * | B | US-5,411,980 | 05-1995 | Ashton et al. | 514/384 |
| * | C | US-5,281,614 | 01-1994 | Ashton et al. | 514/359 |
| * | D | US-4,909,833 | 03-1990 | Kajioka et al. | 504/273 |
| * | E | US-4,318,731 | 03-1982 | Kajioka et al. | 504/273 |
| * | F | US-4,806,145 | 02-1989 | Maravetz, Lester L. | 504/273 |
| | G | US- | | | |
| | H | US- | | | |
| | I | US- | | | |
| | J | US- | | | |
| | K | US- | | | |
| | L | US- | | | |
| | M | US- | | | |

**FOREIGN PATENT DOCUMENTS**

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Country | Name | Classification |
|---|---|---|---|---|---|---|
| * | N | WO 2004058731 A1 | 07-2004 | World Intellect | DUPLANTIER et al. | C07D249/12 |
| | O | | | | | |
| | P | | | | | |
| | Q | | | | | |
| | R | | | | | |
| | S | | | | | |
| | T | | | | | |

**NON-PATENT DOCUMENTS**

| * | | Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) |
|---|---|---|
| | U | Chang, L., et al., "Potent and Orally Active Angiotension II Receptor Antagonists with Equal Affinity for Human AT1 and AT2 Subtypes," J. Med. Chem., vol. 38(19), pp. 3741-3758 (Sept. 1995), at p. 3752, lines 18 - 35, compound 58; |
| | V | Chang, L., et al., "Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes," J. Med. Chem., vol. 37(26), pp. 4464-4478 (Dec. 1994), at p. 4468, compound 13, p. 4469, compound 36; |
| | W | Baxter, A., et al., "Hit-to-Lead Studies: Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," Bioorg. Med. Che. Lett., vol. 13(22), pages 4047-4050 (Nov. 2003), at p. 4048, col. 2, lines 10-14 and Table 1; |
| | X | Baraldi, P., et al., "Synthesis and Biological Activity of N-Arylpiperazine-Modified Analogues of KN-62, a Potent Antagonist of the Purinergic P2X7 Receptor," J. Med. Chem., vol. 46(8), pp. 1318-1329 (Apr. 2003), at p. 1320, col.2,line 30-p.1321, line 8; |

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

| Notice of References Cited | Application/Control No. 10/748,342 | Applicant(s)/Patent Under Reexamination DOMBROSKI ET AL. | |
|---|---|---|---|
| | Examiner Anthony J. Paviglianiti | Art Unit 1626 | Page 2 of 2 |

**U.S. PATENT DOCUMENTS**

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Name | Classification |
|---|---|---|---|---|---|
| | A | US- | | | |
| | B | US- | | | |
| | C | US- | | | |
| | D | US- | | | |
| | E | US- | | | |
| | F | US- | | | |
| | G | US- | | | |
| | H | US- | | | |
| | I | US- | | | |
| | J | US- | | | |
| | K | US- | | | |
| | L | US- | | | |
| | M | US- | | | |

**FOREIGN PATENT DOCUMENTS**

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Country | Name | Classification |
|---|---|---|---|---|---|---|
| | N | | | | | |
| | O | | | | | |
| | P | | | | | |
| | Q | | | | | |
| | R | | | | | |
| | S | | | | | |
| | T | | | | | |

**NON-PATENT DOCUMENTS**

| * | | Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) |
|---|---|---|
| | U | Chang, L., et al., "Triazolinones as Nonpeptide Angiotensin II Antagonists.1.Synthesis and Evaluation as Potent 2,4,5-Trisubstituted Triazolinones," J. Med. Chem., vol. 36(17), pp. 2558–2568 (Aug. 1993), at p. 2560,lines 14–36;p.2561,Table I,cmpds 6,10,14; |
| | V | |
| | W | |
| | X | |

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.